Search results
Showing 1301 to 1350 of 3765 results for treatment
Awaiting development Reference number: GID-TA11870 Expected publication date: TBC
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Digital self-help for eating disorders: early value assessment
In development Reference number: GID-HTE10058 Expected publication date: TBC
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
Short-term bridging treatment with glucocorticoids:- What is the clinical and cost effectiveness of short-term bridging...
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.
future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line...
Question Early and late-onset meningitis: What is the optimal antibiotic treatment regimen for early-onset neonatal meningitis? Any...
and prescriptive factors are important in determining the choice of PTSD treatment? Any explanatory notes(if applicable) To find out why...
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Recommendation ID NG198/1 Question Oral isotretinoin treatment: What is the efficacy of reduced dose oral isotretinoin in the management
migraine:- Is amitriptyline a clinically and cost effective prophylactic treatment for recurrent migraine? Any explanatory notes(if...
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
biomarkers accurately classify recurrence, progression and response to treatment? Any explanatory notes(if applicable) For a short...
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable)...
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.
want to think about having bisphosphonate treatment. You can choose whether to have bisphosphonate treatment or not. There...
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
with symptoms unresponsive to antipsychotic medication and psychological treatment combined? Any explanatory notes(if applicable) The...
This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.
View quality statements for QS104Show all sections
Sections for QS104
- Quality statements
- Quality statement 1: Acute cholecystitis
- Quality statement 2: Urgent endoscopic retrograde cholangiopancreatography within 72 hours
- Quality statement 3: Emergency endoscopic retrograde cholangiopancreatography within 24 hours
- Quality statement 4: Advice to prevent symptoms
- About this quality standard
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup of people with osteoarthritis? Any...
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?...
headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache? Any explanatory notes(if...
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)
Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making
cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with...
Workplace health: long-term sickness absence and capability to work (QS202)
This quality standard covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence. It covers everyone aged over 16 in full-time or part-time employment (paid or unpaid). It describes high-quality care in priority areas for improvement.
View quality statements for QS202Show all sections
Sections for QS202
In development Reference number: GID-TA11675 Expected publication date: TBC
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Digitally enabled therapies for adults with depression: early value assessment (HTG675)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.
This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.
View quality statements for QS158Show all sections
NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA978
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Evidence-based recommendations on using coronary artery stents in adults.